AUM: $696M · Form ADV, 27 Mar 2026
| i | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nasdaq: PTCT | Current | Pharmaceutical Preparations | COM | 875,349 | -43,497 | -4.7% | 1.05% | $57M | -$18M | 8.44% | $4.9B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: IOVA | Current | Biological Products, (No Diagnostic Substances) | COM | 3,471,456 | -1,824,753 | -34.5% | 0.75% | $51M | +$29M | 7.65% | $3.4B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: INSM | Current | Pharmaceutical Preparations | COM PAR $.01 | 443,645 | +29,665 | +7.2% | 0.20% | $51M | +$6M | 7.53% | $31.7B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: ACAD | Current | Pharmaceutical Preparations | COM | 2,485,608 | +2,485,608 | New | 1.44% | $50M | +$50M | 7.45% | $3.0B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: BMRN | Current | Pharmaceutical Preparations | COM | 642,455 | -40,322 | -5.9% | 0.33% | $39M | -$0.5M | 5.73% | $11.9B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: MIRM | Current | Pharmaceutical Preparations | COM | 387,314 | -18.9% | 0.59% | $33M | -$8M | 4.93% | $6.2B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | ||
| UNITED THERAPEUTICS Corp | Nasdaq: UTHR | Current | Pharmaceutical Preparations | COM | 58,875 | -3,712 | -5.9% | 0.14% | $32M | -$2M | 4.75% | $23.8B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: DYN | Current | Pharmaceutical Preparations | COM | 1,881,927 | +234,406 | +14.2% | 1.00% | $30M | -$6M | 4.51% | $3.0B | Q3 2026 | 16 Nov 2026 | Q1 2025 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: BIIB | Current | Biological Products, (No Diagnostic Substances) | COM | 132,918 | -7,361 | -5.2% | 0.09% | $30M | -$0.3M | 4.47% | $36.5B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: ANAB | Current | Pharmaceutical Preparations | COM | 595,264 | -8,225 | -1.4% | 1.99% | $30M | -$11M | 4.45% | $1.4B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: CDNA | Current | Services-Medical Laboratories | COM | 424,601 | -107,269 | -20.2% | 0.81% | $28M | +$12M | 4.11% | $3.8B | Q3 2026 | 16 Nov 2026 | Q3 2025 | Q3 2026 | 13F, Q3 2026 | |
| First Tracks Biotherapeutics, Inc. | Nasdaq: TRAX | Current | Pharmaceutical Preparations | ORD SHS | 741,097 | +137,608 | +22.8% | 1.76% | $26M | +$14M | 3.91% | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: IRON | Current | Pharmaceutical Preparations | COM | 396,529 | -20,117 | -4.8% | 0.87% | $26M | -$5M | 3.86% | $3.5B | Q3 2026 | 16 Nov 2026 | Q2 2025 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: NVCR | Current | Surgical & Medical Instruments & Apparatus | ORD SHS | 1,209,774 | -70,665 | -5.5% | 1.03% | $19M | -$0.1M | 2.87% | $1.2B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: BCAX | Current | Pharmaceutical Preparations | COM | 689,344 | +138,936 | +25.2% | 1.04% | $13M | -$4M | 1.91% | $605M | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: ANNX | Current | Pharmaceutical Preparations | COM | 2,811,222 | -136,868 | -4.6% | $12M | -$5M | 1.77% | $651M | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 | ||
| Syndax Pharmaceuticals Inc | Nasdaq: SNDX | Current | Pharmaceutical Preparations | COM | 596,356 | -268,630 | -31.1% | 0.67% | $11M | -$8M | 1.67% | $822M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: CLDX | Current | In Vitro & In Vivo Diagnostic Substances | COM NEW | 343,101 | -56,755 | -14.2% | 0.44% | $11M | -$4M | 1.65% | $2.2B | Q3 2026 | 16 Nov 2026 | Q1 2026 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: RARE | Current | Pharmaceutical Preparations | COM | 710,029 | +113,534 | +19.0% | 0.70% | $11M | -$9M | 1.59% | $1.8B | Q3 2026 | 16 Nov 2026 | Q2 2025 | Q3 2026 | 13F, Q3 2026 | |
| Prothena Corp PLC | Current | SHS | 1,129,363 | -13,792 | -1.2% | $9M | -$2M | 1.41% | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | ||||
| Nasdaq: TVTX | Current | Pharmaceutical Preparations | COM | 158,946 | -8,579 | -5.1% | 0.17% | $9M | -$0.2M | 1.39% | $4.6B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: ALKS | Current | Pharmaceutical Preparations | SHS | 203,680 | -38,880 | -16.0% | 0.12% | $8M | -$4M | 1.23% | $7.8B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: CMPX | Current | Biological Products, (No Diagnostic Substances) | COM | 7,148,673 | +1,316,860 | +22.6% | 3.97% | $7M | -$5M | 1.11% | $122M | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: AGIO | Current | Pharmaceutical Preparations | COM | 200,984 | -12,617 | -5.9% | 0.34% | $7M | -$1M | 0.99% | $1.7B | Q3 2026 | 16 Nov 2026 | Q1 2025 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: TSHA | Current | Biological Products, (No Diagnostic Substances) | COM SHS | 1,337,217 | -54,165 | -3.9% | 0.41% | $7M | -$3M | 0.97% | $1.2B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: ACRS | Current | Pharmaceutical Preparations | COM | 1,156,396 | -457,034 | -28.3% | 0.73% | $6M | -$2M | 0.90% | $555M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: CAPR | Current | Pharmaceutical Preparations | COM NEW | 548,071 | +318,308 | +138.5% | 0.94% | $5M | -$0.3M | 0.77% | $438M | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: ALGN | Current | Orthopedic, Prosthetic & Surgical Appliances & Supplies | COM | 31,389 | 0 | 0.0% | 0.04% | $5M | -$0.7M | 0.68% | $11.3B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Newamsterdam Pharma Company | Current | ORDINARY SHARES | 162,874 | +118,515 | +267.2% | $4M | +$2M | 0.59% | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 | ||||
| Nasdaq: TARA | Current | Biological Products, (No Diagnostic Substances) | COM STK | 1,035,964 | +1,035,964 | New | 1.68% | $3M | +$3M | 0.47% | $148M | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: CTNM | Current | Pharmaceutical Preparations | CL A | 220,226 | +220,226 | New | $3M | +$3M | 0.44% | $355M | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 | ||
| NYSE: EW | Current | Orthopedic, Prosthetic & Surgical Appliances & Supplies | COM | 33,640 | 0 | 0.0% | 0.01% | $3M | -$0.1M | 0.43% | $59.7B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: VSTM | Current | Pharmaceutical Preparations | COM NEW | 325,480 | +15,795 | +5.1% | 0.26% | $3M | +$1M | 0.39% | $864M | Q3 2026 | 16 Nov 2026 | Q1 2026 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: NBIX | Current | Biological Products, (No Diagnostic Substances) | COM | 18,117 | 0 | 0.0% | 0.02% | $3M | -$0.5M | 0.38% | $15.8B | Q3 2026 | 16 Nov 2026 | Q1 2025 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: SGMT | Current | Pharmaceutical Preparations | COM SER A | 250,000 | 0 | 0.0% | $2M | +$0.5M | 0.37% | $692M | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q3 2026 | 13F, Q3 2026 | ||
| Adlai Nortye Group Ltd. | Nasdaq: ANL | Current | Pharmaceutical Preparations | SPONSORED ADS | 149,490 | +149,490 | New | $2M | +$2M | 0.36% | $583M | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: STOK | Current | Pharmaceutical Preparations | COM | 84,631 | 0 | 0.0% | 0.13% | $2M | -$0.6M | 0.33% | $1.8B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: ORKA | Current | Pharmaceutical Preparations | COM | 25,563 | -7,983 | -23.8% | 0.04% | $2M | -$1M | 0.32% | Q3 2026 | 16 Nov 2026 | Q3 2025 | Q3 2026 | 13F, Q3 2026 | ||
| Nasdaq: CRSP | Current | Biological Products, (No Diagnostic Substances) | NAMEN AKT | 36,949 | -2,656 | -6.7% | 0.04% | $2M | -$0.1M | 0.30% | $3.8B | Q3 2026 | 16 Nov 2026 | Q2 2025 | Q3 2026 | 13F, Q3 2026 | |
| Pyxis Oncology, Inc. | Nasdaq: PYXS | Current | Pharmaceutical Preparations | COMMON STOCK | 864,277 | 0 | 0.0% | 0.72% | $2M | -$0.6M | 0.30% | $201M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: CYTK | Current | Pharmaceutical Preparations | COM NEW | 30,036 | -2,159 | -6.7% | 0.02% | $2M | -$0.8M | 0.29% | $7.2B | Q3 2026 | 16 Nov 2026 | Q1 2026 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: BNTX | Current | Biological Products, (No Diagnostic Substances) | SPONSORED ADS | 19,614 | 0 | 0.0% | 0.01% | $2M | +$0.1M | 0.29% | $20.2B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| NYSE: NUVB | Current | Pharmaceutical Preparations | COM CL A | 326,609 | 0 | 0.0% | 0.09% | $2M | -$0.0M | 0.27% | $1.3B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: XENE | Current | Pharmaceutical Preparations | COM | 47,902 | -3,443 | -6.7% | 0.05% | $2M | -$1M | 0.27% | $3.7B | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 | |
| NYSE: HUM | Current | Hospital & Medical Service Plans | COM | 3,985 | 0 | 0.0% | <0.01% | $2M | -$0.1M | 0.23% | $45.6B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: CMPS | Current | Pharmaceutical Preparations | SPONSORED ADS | 115,616 | 0 | 0.0% | 0.08% | $1M | -$0.2M | 0.21% | $1.2B | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 | |
| eHealth, Inc. | Nasdaq: EHTH | Current | Insurance Agents, Brokers & Service | COM | 1,431,535 | -51,262 | -3.5% | 4.42% | $1M | -$1M | 0.15% | $11M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 |
| Xeris Biopharma Holdings, Inc. | Nasdaq: XERS | Current | Pharmaceutical Preparations | COM | 104,410 | 0 | 0.0% | 0.06% | $1.0M | +$0.2M | 0.15% | $3.0B | Q3 2026 | 16 Nov 2026 | Q1 2026 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: URGN | Current | Pharmaceutical Preparations | COM | 24,500 | 0 | 0.0% | 0.05% | $1.0M | +$0.1M | 0.15% | $1.6B | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | |
| Nasdaq: MDGL | Current | Pharmaceutical Preparations | COM | 1,787 | 0 | 0.0% | 0.01% | $0.9M | -$0.1M | 0.13% | $9.2B | Q3 2026 | 16 Nov 2026 | Q1 2026 | Q3 2026 | 13F, Q3 2026 | |
| Cybin Inc | Current | COM NEW | 72,634 | +72,634 | New | $0.9M | +$0.9M | 0.13% | Q3 2026 | 16 Nov 2026 | Q3 2026 | Q3 2026 | 13F, Q3 2026 | ||||
| Nasdaq: BCYC | Current | Pharmaceutical Preparations | SPONSORED ADS | 188,351 | -13,539 | -6.7% | $0.7M | -$0.2M | 0.10% | $214M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 | ||
| NYSE: INSP | Current | Surgical & Medical Instruments & Apparatus | COM | 8,772 | 0 | 0.0% | 0.03% | $0.6M | +$0.2M | 0.09% | $1.6B | Q3 2026 | 16 Nov 2026 | Q4 2025 | Q3 2026 | 13F, Q3 2026 | |
| ABEONA THERAPEUTICS INC. | Nasdaq: ABEO | Current | Pharmaceutical Preparations | COM NEW | 108,865 | 0 | 0.0% | 0.19% | $0.6M | -$0.1M | 0.09% | $151M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 |
| Proqr Thrapeutics N V | Current | SHS EURO | 188,807 | 0 | 0.0% | $0.3M | -$0.0M | 0.05% | Q3 2026 | 16 Nov 2026 | Q3 2025 | Q3 2026 | 13F, Q3 2026 | ||||
| Aldeyra Therapeutics, Inc. | Nasdaq: ALDX | Current | Pharmaceutical Preparations | COM | 155,709 | 0 | 0.0% | 0.26% | $0.2M | -$0.1M | 0.03% | $44M | Q3 2026 | 16 Nov 2026 | Q3 2024 | Q3 2026 | 13F, Q3 2026 |
| Nasdaq: ACHC | Exited | Services-Specialty Outpatient Facilities, NEC | COM | 0 | -2,864,096 | -100.0% | -$72M | $3.2B | Q3 2026 | 16 Nov 2026 | Q2 2026 | Q2 2026 | 13F, Q2 2026 | ||||
| Exited | COM | 0 | -1,113,045 | -100.0% | -$16M | Q2 2026 | 17 Aug 2026 | Q3 2024 | Q1 2026 | 13F, Q1 2026 | |||||||
| Nasdaq: ALNY | Exited | Pharmaceutical Preparations | COM | 0 | -32,320 | -100.0% | -$15M | $19.8B | Q4 2025 | 17 Feb 2026 | Q3 2024 | Q3 2025 | 13F, Q3 2025 | ||||
| Gossamer Bio Inc | Exited | COM | 0 | -4,471,592 | -100.0% | -$14M | Q1 2026 | 15 May 2026 | Q3 2024 | Q4 2025 | 13F, Q4 2025 | ||||||
| Nasdaq: SRPT | Exited | Pharmaceutical Preparations | COM | 0 | -210,258 | -100.0% | -$13M | $1.5B | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | ||||
| STAAR SURGICAL CO | Nasdaq: STAA | Exited | Ophthalmic Goods | COM | 0 | -791,879 | -100.0% | -$13M | $1.3B | Q3 2025 | 14 Nov 2025 | Q3 2024 | Q2 2025 | 13F, Q2 2025 | |||
| Revance Therapeutics Inc | Exited | COM | 0 | -1,611,787 | -100.0% | -$8M | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||||
| Sage Therapeutics Inc | Exited | COM | 0 | -1,010,833 | -100.0% | -$7M | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||||
| Avidity Biosciences Inc | Exited | COM | 0 | -109,831 | -100.0% | -$5M | Q4 2025 | 17 Feb 2026 | Q2 2025 | Q3 2025 | 13F, Q3 2025 | ||||||
| Denali Therapeutics Inc. | Nasdaq: DNLI | Exited | Biological Products, (No Diagnostic Substances) | COM | 0 | -234,582 | -100.0% | -$5M | $2.9B | Q2 2026 | 17 Aug 2026 | Q2 2025 | Q1 2026 | 13F, Q1 2026 | |||
| Acelyrin Inc | Exited | COM | 0 | -1,792,895 | -100.0% | -$4M | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | ||||||
| Nevro Corp | Exited | COM | 0 | -750,371 | -100.0% | -$3M | Q1 2025 | 15 May 2025 | Q3 2024 | Q4 2024 | 13F, Q4 2024 | ||||||
| Verve Therapeutics Inc | Exited | COM | 0 | -575,817 | -100.0% | -$3M | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | ||||||
| Karyopharm Therapeutics Inc | KPTIQ | Exited | COM | 0 | -187,911 | -100.0% | -$0.8M | Q3 2025 | 14 Nov 2025 | Q3 2024 | Q2 2025 | 13F, Q2 2025 | |||||
| Elevation Oncology Inc | Exited | COM | 0 | -1,298,097 | -100.0% | -$0.8M | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||||
| Yarrow Bioscience, Inc. | Nasdaq: YARW | Exited | Pharmaceutical Preparations | COM | 0 | -445,434 | -100.0% | -$0.7M | $217M | Q3 2025 | 14 Nov 2025 | Q3 2024 | Q2 2025 | 13F, Q2 2025 | |||
| Jasper Therapeutics, Inc. | Nasdaq: JSPR | Exited | Biological Products, (No Diagnostic Substances) | COM NEW | 0 | -30,651 | -100.0% | -$0.7M | $0.5M | Q1 2025 | 15 May 2025 | Q4 2024 | Q4 2024 | 13F, Q4 2024 | |||
| Nasdaq: ALMS | Exited | Pharmaceutical Preparations | COM | 0 | -143,437 | -100.0% | -$0.4M | $562M | Q3 2025 | 14 Nov 2025 | Q2 2025 | Q2 2025 | 13F, Q2 2025 | ||||
| Bluebird Bio Inc | Exited | COM | 0 | -604,260 | -100.0% | -$0.3M | Q4 2024 | 14 Feb 2025 | Q3 2024 | Q3 2024 | 13F, Q3 2024 | ||||||
| Instil Bio, Inc. | Nasdaq: TIL | Exited | Biological Products, (No Diagnostic Substances) | COM NEW | 0 | -11,165 | -100.0% | -$0.2M | $38M | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | |||
| RELMADA THERAPEUTICS, INC. | Nasdaq: RLMD | Exited | Pharmaceutical Preparations | COM | 0 | -495,146 | -100.0% | -$0.1M | $332M | Q2 2025 | 14 Aug 2025 | Q3 2024 | Q1 2025 | 13F, Q1 2025 | |||
| Generation Bio Co | Exited | COM | 0 | -15,047 | -100.0% | -$0.1M | Q1 2026 | 15 May 2026 | Q3 2024 | Q4 2025 | 13F, Q4 2025 | ||||||
| Akari Therapeutics Plc-Adr | Exited | COM | 0 | -146,024 | -100.0% | -$0.0M | Q1 2026 | 15 May 2026 | Q4 2024 | Q4 2025 | 13F, Q4 2025 |